GSK Is Getting Ready For A Return To The ’90s
Executive Summary
Though it has left behind the “industrialized” R&D approaches from the 1990s, Glaxo thinks its R&D revolution has produced strong growth that will get it back into major markets and maintain an output of three to five significant drug approvals per year. With that progress in sight, the firm is ready to transform its manufacturing and commercial model in the same way it recreated R&D.
You may also be interested in...
GSK/ChemoCentryx Crohn’s Failure May Sink Hefty Phase III Program
SHIELD-1 failure puts the entire 2,500-patient plus Phase III clinical program in limbo as GSK rethinks its Crohn’s disease approach and partner ChemoCentryx’s stock loses close to half its value.
Deals of the Week Looks at Ultra-Orphan Drug Pricing
In the first half of 2013, two drugs for serious, ultra-rare diseases will have launched in the U.S. priced at $250,000 annually. One is encountering minimal resistance among payers; the other is expected to face a hard road. Plus a look at Celgene/Forma, Bayer/Conceptus, Soligenix/Intrexon; Regeneron/Sanofi and more.
AZ’s Make Or Break Moment Comes Down To Business Development
AstraZeneca needs new assets to change investors’ dismal outlook for the company. With a new CEO installed, an R&D shakeup underway, and a new portfolio strategist joining in May, AstraZeneca will embark on an ambitious acquisition and partnering strategy in 2013.